4. The novel cell-based assay, in combination with a variety of immunochemical approaches, has been used to identify and characterize monoclonal antibodies that neutralize VEGF-B activity.
INTRODUCTION
In vivo growth factor-based stimulation of de novo blood vessel formation represents a novel experimental approach to the treatment of cardiovascular disease. In various animal models of disease, this strategy, now commonly referred to as 'therapeutic angiogenesis', has been highly effective, resulting in increased blood flow into ischaemic tissues and, in some cases, improvement in relevant functional parameters. [1] [2] [3] Protein-or gene-based delivery of factors that directly influence endothelial cell function, including transcription factors downstream from the receptorligand interaction, have been the focus of interest. 4, 5 More recently, approaches targeting regulatory cell populations, such as cells of the monocyte-macrophage lineage, have also proved to be highly effective. 6, 7 Much of this preclinical analysis has focused on the various isoforms of vascular endothelial growth factor (VEGF or VEGF-A). This growth factor is critical for blood vessel formation throughout embryogenesis and it is an important regulator of both post-natal physiological and diseaseassociated 'pathological' angiogenesis. 8, 9 Vascular endothelial growth factor-A is now recognized as the founding member of a family of growth factors that bind differentially to three receptor tyrosine kinases (namely VEGF-R1, -R2 and -R3), as well as the semaphorin receptors neuropilin 1 and 2 (NP-1 and -2). 9 Despite evidence of an important role for the VEGF-R1-specific ligand VEGF-B in heart development and function 10 and recent evidence of a central role for VEGF-R1-specific ligands in pathological angiogenesis, 11 the potential of VEGF-B in therapeutic angiogenesis remains relatively unexplored. To facilitate such an analysis, we have developed expression and refolding strategies for various VEGF-B isoforms. In addition, we have developed a novel cell-based assay for the analysis of recombinant protein activity and have used this assay to identify monoclonal antibody (mAb)-based antagonists of VEGF-B.
hygromycin resistance were subsequently selected and maintained in media supplemented with puromycin (25 g/mL) or hygromycin (60 g/mL), respectively. The 293A12 cells were derived from 293T cells following stable transfection with a luciferase reporter under the control of a signal transducers and activators of transcription (STAT)-3 promoter. 12 When stimulated with cytokines that activate STAT-3, such as leukaemia inhibitory factor (LIF) and interleukin (IL)-6, luciferase expression is induced 10-15- 
Expression, purification and refolding of VEGF-B isoforms
Recombinant VEGF-B 167 was expressed in Escherichia coli using the pET15b vector with downstream purification and refolding, as described previously. 13 The coding region of the mature human VEGF-B 10 − 108 protein was amplified using polymerase chain reaction (PCR; one cycle at 95 ° C/2 min; 30 cycles at 94 ° C/1 min, 60 ° C/1 min, 72 ° C/1 min; one cycle at 72 ° C/ 15 min; 1.5 U Expand High Fidelity PCR System enzyme mix; Roche Diagnostics, Mannheim, Germany) to introduce in-frame Bam HI and Hind III restriction enzyme sites at the 5 ′ -and 3 ′ ends, respectively, using the following oligonucleotides: 5 ′ -oligo 5 ′ -CACGGATCCGCAGCACACTAT-CACCAGAGGAAAG-3 ′ ; 3 ′ -oligo 5 ′ -GCATAAGCTTTCACTTTTTTTT-AGGTCTGCATTC-3 ′ . The resulting PCR-derived DNA fragment was digested with Bam HI and Hind III and ligated into Bam HI and Hind III digested pQE30 (Qiagen, Hilden, Germany). The VEGF-B 10 − 108 -pQE30 DNA was transformed into M15[pREP4] E. coli (Qiagen) using an electroporator (Bio-Rad, Hercules, CA, USA) according to the manufacturer's instructions. When expressed in E. coli , the VEGF-B 10 − 108 protein has an additional 16 amino acids at the N-terminus that incorporate a His 6 tag and a Genenase I cleavage site. The VEGF-B 10 − 108 protein was isolated from E. coli inclusion bodies and purified and refolded as described previously. 13 The coding region of mature human VEGF-B 186 was amplified by PCR and cloned into the pET15b vector. In contrast with the other isoforms, VEGF-B 186 was purified directly from whole E. coli cell lysate rather than inclusion bodies. Pelleted cells were suspended in a buffer comprising 6 mol/L guanidine hydrochloride (GdCl), 0.1 mol/L NaH 2 PO 4 , 10 mmol/L Tris-HCl, 10 mmol/L 2-mercaptoethanol, 0.02% Tween-20, pH 8.0, at 10 mL/g cells and incubated overnight at 37 ° C. After centrifugation (30 000 g, 4°C) the supernatant was decanted and filtered through a 1.2 m filter. Nickel affinity chromatography and further downstream purification and refolding were as described previously.
13
Generation of chimeric receptor cDNA cDNA encoding chimeric receptors were generated by splice overlap PCR (SO-PCR), as described previously.
14 The coding region of extracellular immunoglobulin (Ig) domains (D) 1-4 and 1-3 of human VEGF-R1 were amplified by PCR (one cycle 96°C/2 min; 35 cycles 94°C/30 s, 55°C/30 s, 68°C/1.5 min; 1.5 U Expand High Fidelity PCR System enzyme mix; Roche Diagnostics) using the following oligonucleotides: 5′-oligo 5′-ATATGGCGCGCCTAGTCAGCTACTGGGACACCGGGGT-C-3′; 3′-oligo (domains 1-4) 5′CAGGCACGACTATGGCTTCAATTTCT-CCGGCCTTTTCGTAAATCTGGGGTTTTCAC-3′; 3′-oligo (domains 1-3) 5′-CACGACTATGGCTTCAATTTCTCCTATATGCACTGAGGTG-TTAACAGATTTG-3′. Similar PCR conditions were used to amplify the human gp130 transmembrane and cytoplasmic domains using the following oligonucleotides: 5′-oligo 5′-ACGTACGCGTTCACTGAGGCATGTAGC-CGCCTTGCCG-3′; 3′-oligo 5′-GGAGAAATTGAAGCCATAGTCGT-GCCTGTTTGCTTAGC-3′.
To generate chimeric cDNA, the PCR products were mixed and a further PCR using the same conditions with the 5′ sense VEGF-R1 oligonucleotide and the 3′ antisense gp130 oligonucleotide was performed. This PCR product was designed to incorporate a 5′-Asc1 site and a 3′ Mlu1 restriction enzyme site and, after digestion with these enzymes, was ligated into an Mlu1-digested mammalian expression vector, namely pEFBOS-S-FLAG.
12
Expression and purification of His6-VEGF-R1 Ig domain 2
The coding region of Ig domain 2 (D2) of the human VEGF-R1 protein (residues 129-229) was amplified by PCR and ligated into pQE30 vector (Qiagen). The VEGF-R1D2 protein was isolated and refolded using a previously described protocol 15 and further purified by reverse-phase HPLC.
Biosensor analysis of receptor binding
The binding of the VEGF-B isoforms to VEGF-R1D2 was assessed by surface plasmon resonance (Biosensor 2000; Biacore, Uppsala, Sweden). The target molecules were immobilized to a CM5 dextran chip using amine coupling chemistry according to the manufacturer's instructions. Briefly, 35 L of a 1 : 1 mixture of N-hydroxysuccinimide and N-ethyl-N′-(3-dimethylaminopropyl)carbodiimide hydrochloride was injected onto the sensorchip at a flow rate of 5 L/min to activate the sensor surface. Test and negative control (LIF) proteins were resuspended in 20 mmol/L sodium acetate, pH 4.5 (final concentration 7-20 g/mL), and injected directly onto the sensor surface. Post-coupling, 50 mmol/L diaminoethane, pH 9.0, was used to quench residual activated sites on the biosensor surface. Two cycles of 0.1 mol/L phosphoric acid (30 L; 50 L/min) were performed at the end of each run to regenerate the sensorchip surface.
Purified VEGF-R1D2 (620 g/mL) was diluted to varying concentrations in 0.1% w/v bovine serum albumin, 20 mmol/L HEPES, 0.15 mol/L NaCl, 0.005% v/v Tween 20, 3.4 mmol/L EDTA, pH 7.4. Receptor binding was monitored simultaneously on VEGF-B10−108, VEGF-B167, VEGF-B186 and murine LIF control channel at a flow rate of 5 L/min. Scatchard analysis was used to determine binding kinetics at steady state equilibrium.
RESULTS

Expression and biochemical analysis of VEGF-B isoforms
Vascular endothelial growth factor-B167, VEGF-B186 and VEGF-B10−108 were expressed in E. coli as N-terminal His6-tagged proteins. Metal affinity chromatography under reducing and denaturing conditions was used to purify monomeric VEGF-B proteins and, following dialysis refolding, dimeric protein was separated from monomeric and high molecular weight multimeric forms via a combination of reverse-phase HPLC and hydrophillic chromatography. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis analysis of the three refolded isoforms is shown in Fig. 1a .
The receptor binding characteristics of the purified and refolded VEGF-B isoforms were examined using surface plasmon resonance and recombinant VEGF-R1D2. Vascular endothelial growth factor-R1D2 has been demonstrated previously to represent the minimal ligand binding domain of VEGF-R1. 15 The three forms of VEGF-B were immobilized on separate channels of the CM5 sensorchip, while murine LIF was immobilized to the fourth channel to serve as a negative control. Interaction with VEGF-R1D2 was monitored on all channels simultaneously. The molecules VEGF-B10-108, VEGF-B167 and VEGF-B186 were found to interact with VEGF-R1D2 with similar kinetics (Fig. 1b , VEGF-B186 only as an example; Fig. 1c) . The truncated VEGF-B10-108 appears to have a slightly higher affinity for VEGF-R1D2 (KD 0.8 nmol/L) than that exhibited by either VEGF-B167 (KD 1.5 nmol/L) or VEGF-B186 (KD 2.0 nmol/L).
Development of a novel cell-based VEGF-B assay
Endothelial cells do not proliferate in response to VEGF-R1 ligands and no simple biological assay of either placenta growth factor (PlGF) or VEGF-B has been described. To address this issue, we have generated chimeric receptors based on the extracellular domain of VEGF-R1 and the transmembrane and cytoplasmic domains of the shared cytokine receptor gp130. Using SO-PCR extracellular D1-D4 or D1-D3 of VEGF-R1 were fused to the gp130 transmembrane (residues 574-595) and cytoplasmic domains (residues 595-918; Fig. 2a ). Chimeric receptor cDNA was subsequently cloned into the pEFBOS-S-FLAG vector for expression as N-terminal FLAG-tagged proteins. Chimeric receptor expression was confirmed following transient transfection 293T cells and western blot analysis using anti-FLAG antibodies (Fig. 2b) .
For assay development, the construct incorporating VEGF-R1 D1-D4 and a vector incorporating a hygromycin resistance gene were cotransfected into 293A12 cells. Following hygromycin selection, isolated resistant colonies were picked and expanded, then assayed for luciferase activity after incubation with VEGF-A. Eleven of 63 colonies assayed expressed luciferase in response to VEGF-A and colony 2.1.19 was subsequently cloned by limit dilution. Concentration-response analysis of clone 2.1.19.25 to VEGF-A is shown in Fig. 2c . Upon further analysis, this response was shown to be completely inhibited by soluble VEGF-R1-IgGFc chimeric receptor protein (R&D Systems, Abingdon, UK; Fig. 2d ). As expected, the VEGF-R1-IgG-Fc chimeric protein did not inhibit 2.1.19.25 luciferase production in response to LIF. Over a large number of assays, the VEGF-A signal to background ratio has varied between 2.5 and 3.
Assay of recombinant VEGF-B and characterization of VEGF-B-specific neutralizing mAbs
Refolded VEGF-B isoforms were assessed for biological activity in the 2.1.19.25 cell-based assay. Both VEGF-B167 and VEGF-B10−108 were shown to be active (Fig. 3a) , although the signal to background ratio was routinely less than that observed for VEGF-A. In addition, the EC50 for both isoforms of VEGF-B was routinely in the order of 200-500 ng/mL and for VEGF-A the EC50 was approximately 50-100 ng/mL. The VEGF-B186 preparations have not induced luciferase expression in the cell-based assay, despite interaction with VEGF-R1 in biosensor-based analysis.
Monoclonal antibodies that bind to and inhibit the biological activity of VEGF-B would represent valuable tools for the characterization of VEGF-B function. A panel of mAbs raised against the VEGF-B167 isoform and characterized using standard immunochemical techniques (PD Scotney et al., unpubl. obs., 2001) was screened for activity in the 2.1.19.25 cell-based assay described above. Results presented in Fig. 3b demonstrate that mAb 2H10, but not control unrelated mAb 6A9, was able to inhibit VEGF-B activity across all concentrations tested. Interestingly, the mAb reduced the 2.1.19.25 response to below background levels, suggesting the possibility that at least a proportion of the background response may be due to VEGF-B activity within the fetal calf serum-supplemented assay media. As expected, 2H10 had no impact on the 2.1.19.25 response to VEGF-A (data not shown). In contrast, mAb 7C3 appeared to exhibit agonist activity at low concentrations of VEGF-B. Five additional VEGF-B-specific mAbs were assessed for activity in the 2.1.19.25 assay and 
DISCUSSION
The various isoforms of VEGF-A regulate endothelial cell differentiation, proliferation and function and a substantial body of data suggests that the key receptor mediating these activities is VEGF-R2. 16 Administered as either the gene or protein, VEGF-A appears to mediate a therapeutic effect in animal models of cardiovascular disease and human phase II clinical trials are currently in progress. 5 Other members of the VEGF family are also being assessed in both preclinical and clinical studies. Vascular endothelial growth factor-C has been demonstrated to be effective in the rabbit model of limb ischaemia 17 and is currently in phase I/II trials for peripheral vascular disease.
The potential of the VEGF-R1-specific ligands, namely VEGF-B and PlGF, is more problematic primarily due to controversy surrounding the precise role of this receptor. 18 Recently, however, data from PlGF gene knockout mice have provided direct evidence of a key role for VEGF-R1 signalling in pathological angiogenesis. 11 When the VEGF-B gene is deleted by homologous recombination, post-natal heart size is significantly reduced and there is a defect in left ventricular function: repayment of flow-debt in reactive hyperaemia analysis is impaired and there is an elevated end-diastolic pressure following ischaemia and reperfusion. 10 This phenotype, which suggests an underlying defect in the coronary vasculature, is consistent with the high-level expression of VEGF-B mRNA in the developing and post-natal heart 19, 20 and clearly identifies a potential application for VEGF-B in the treatment of ischaemic heart disease.
Analysis of the therapeutic potential of VEGF-B in animal models of cardiovascular disease requires substantial quantities of active recombinant protein. Although VEGF family members have a complex secondary structure, there has been considerable success in refolding these proteins from insoluble inclusion bodies. 21 We have previously described a protocol for production of dimeric VEGF-B167 based on E. coli fermentation, inclusion body isolation and dialysis refolding. In the present study, we have applied a similar strategy to express, purify and refold the other naturally occurring isoform and a truncated form of the protein that retains the core cystine-knot motif. All three proteins were purified as homodimers and demonstrated to interact with the minimal ligand binding domain of VEGF-R1. The relatively low calculated KD values reflect the nature of the molecular interaction on the biosensor chip compared with high-affinity binding that results from receptor dimerization at a cell surface.
Although biosensor analysis indicates appropriate folding within each monomeric subunit, it does not confirm correct interchain disulphide bond formation to yield biologically active dimer. To date, the biological assay of VEGF-R1 ligand activity has been based on relatively complex readouts, such as monocyte migration, smooth muscle cell matrix metalloproteinase production and osteoclast function. [22] [23] [24] The simple chimeric receptor-based assay we have described uses a reporter gene readout and was used to demonstrate the activity of VEGF-B167 and VEGF-B10−108. This approach to assay development has been used previously for a number of cytokines, including, for example, VEGF-A. 25 Although both isoforms were clearly active, the level of activity was lower than expected particularly when compared with that observed for VEGF-A. This may indicate that a proportion of each of the VEGF-B isoforms is misfolded or that the N-terminal His6 tag used for affinity chromatography in some way interferes with receptor dimerization. Alternatively, there may be an issue with the chimeric receptor such that dimerization is more efficient in the presence of VEGF-A compared with VEGF-B. Surprisingly, we
have not yet detected activity of refolded VEGF-B186 protein. While the problem may again be misfolding or there may be inappropriate dimerization as noted above, Makinen et al. 26 have reported that VEGF-B186 expressed in mammalian cells is processed at the C-terminus and it is only after this processing occurs that it is able to interact with NP-1. It is possible that the full-length C-terminal domain retained in the E. coli-expressed protein may interfere with receptor dimerization and signalling.
In addition to allowing demonstration of recombinant protein biological activity, the new cell-based assay has facilitated the identification of VEGF-B-specific neutralizing mAbs. While these reagents will find application in on-going large animal-based analysis of VEGF-B therapeutic potential, they are also being used to assess the role of VEGF-B in various pathologies. Other members of the VEGF family have been implicated as key mediators of the angiogenesis associated with pathologies such as tumour development and metastasis, rheumatoid arthritis and a range of ocular conditions. 8, 27 It will be of considerable interest to determine the role, if any, of VEGF-B in these processes.
